Efficacy of sulfasalazine in the treatment of generalized lichen planus: randomized double‐blinded clinical trial on 52 patients

Omidian, Mohammad; A, Ayoobi; Mapar, Mohammad Ali; Feily, Amir; Cheraghian, Bahaman

doi:10.1111/j.1468-3083.2010.03583.x

“…Oral acitretin has been shown to be effective [64]. Many other treatments are used, including mycophenolate mofetil, which efficacy is uncertain, and sulfasalazine in patients with generalized lichen planus [65]. …”

Section: Lichen Planus In Lementioning

confidence: 99%

Cutaneous Manifestations of Systemic Lupus Erythematosus

Uva

¹

,

Miguel

²

,

Pinheiro

³

et al. 2012

Autoimmune Diseases

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.

show abstract

“…Oral acitretin has been shown to be effective [64]. Many other treatments are used, including mycophenolate mofetil, which efficacy is uncertain, and sulfasalazine in patients with generalized lichen planus [65].…”

Section: Lichen Planus In Lementioning

confidence: 99%

Cutaneous manifestations of systemic lupus erythematosus

Devi

¹

,

Saraswathy

²

,

Kopika

³

2018

Int J Res Dermatol

0

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.

show abstract

“…Topical and systemic cyclosporine have been tried with some success. [7] , however, a randomised double-blind study indicated that topical cyclosporine was a less effective, but much more costly regimen than clobetasol. [8] Newer topical calcineurin inhibitors have replaced topical cyclosporine for the treatment of Lichen planus.…”

Section: Medical Treatmentmentioning

confidence: 99%